Skip to content

Study · In vitro (cells) · 1994

1 result

Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor.

Frändberg PA, Muceniece R, Prusis P, Wikberg J, Chhajlani V

Biochemical and biophysical research communications1 Aug 1994Cited by 44 (Europe PMC)

PMID8060302 (opens in a new tab)DOI10.1006/bbrc.1994.2067 (opens in a new tab)PepBankPUB-08060302
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In COS-7 cells, the binding affinity of NDP-MSH remained unchanged between wild type MC1R and the Asp117, Phe179, His209 and His260 alanine mutants.

    In plain wordsIn lab tests on cells, NDP-MSH bound the mutated receptors as well as the normal receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeNDP-MSH binding affinity at MC1R mutants
    Study

    n: not reported in source

    COS-7 cells expressing MC1R mutants
    Comparator
    wild type MC1R
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, the binding affinity for the [Nle4, D-Phe7]-alpha-MSH (NDP-MSH; D-isomer) remain unchanged between the wild type and the mutants.
    2 context sentences
    Summary · context
    Expression of the wild type and the MC1R mutants in COS-7 cells
    Summary · context
    The amino acids Asp117, Phe179, His209 and His260 were targeted for mutation to alanine as they are conserved in the melanocortin receptor family.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.